Dexmedetomidine - Reconnect Labs
Alternative Names: RE-03Latest Information Update: 16 Oct 2025
At a glance
- Originator Reconnect Labs
- Class Antidepressants; Anxiolytics; Behavioural disorder therapies; Drug withdrawal therapies; Hypnosedatives; Imidazoles; Non-opioid analgesics; Sleep disorder therapies; Small molecules
- Mechanism of Action Alpha 2 adrenergic receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Insomnia
Most Recent Events
- 16 Oct 2025 Efficacy data from a phase-I clinical trials in Insomnia released by Reconnect Labs
- 10 Sep 2025 Phase-II clinical trials in Insomnia in Switzerland (Buccal) (NCT06685965)
- 09 Sep 2025 Phase-I clinical trials in Insomnia (In volunteers) in Switzerland (Buccal) prior to September 2025 (Reconnect labs pipeline, October 2025)